PCBP2 Reduced Oxidative Stress-Induced Apoptosis in Glioma through cGAS/STING Pathway by METTL3-Mediated m6A Modification

Xiang Chen,1 Mingchuan Yu,1 Wei Xu,2 Peng Kun,3 Wenbing Wan,3 Xiao Yuhong,1 Jing Ye,1 Yu Liu,1 and Jun Luo1

1Department of Rehabilitation Medicine, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang City, Jiangxi Province, China
2Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, China
3Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, China

Correspondence should be addressed to Jun Luo; junluo888@hotmail.com

Received 2 August 2022; Revised 24 August 2022; Accepted 26 August 2022; Published 11 October 2022

Academic Editor: Md Sayed Ali Sheikh

Copyright © 2022 Xiang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The most prevalent primary malignant tumor of CNS is glioma, which has a dismal prognosis. The theory of oxidative stress is one of the important theories in the study of its occurrence and development mechanism. In this study, the impacts of PCBP2 on glioma sufferers and the possible mechanisms were examined.

Methods. Patients with glioma were obtained from May 2017 to July 2018. Quantitative PCR, microarray analysis, western blot analysis, and immunofluorescence were used in this experiment.

Results. PCBP2 mRNA expression level and protein expression in patients with glioma were upregulated compared with paracancerous tissue. OS and DFS of PCBP2 low expression in patients with glioma were higher than those of PCBP2 high expression. PCBP2 promoted the progression and metastasis of glioma. PCBP2 reduced oxidative stress-induced apoptosis of glioma. PCBP2 suppressed the cGAS/STING pathway of glioma. PCBP2 protein interlinked with cGAS and cGAS was one target for PCBP2. METTL3-mediated m6A modification increases PCBP2 stability.

Conclusion. Along the cGAS-STING signal pathway, PCBP2 decreased the apoptosis that oxidative stress-induced glioma caused, which might be a potential target to suppress oxidative stress-induced apoptosis of glioma.

1. Introduction

50 percent of all brain tumors are gliomas, the most prevalent primary malignant tumor of CNS [1]. It has high invasion characteristics: easy recurrence and poor prognosis, among which glioblastoma (GBM) has the highest degree of malignancy [2]. Even with total surgical resection combined with postoperative concurrent radiotherapy and chemotherapy, only 3% to 5% of GBM sufferers survive for a further 3 years, yet the median survival period for these individuals is still only 14.6 months [3]. Therefore, a study in the realm of molecular biology has traditionally been focused on examining the basic basis of glioma and seeking novel diagnostic and therapeutic targets [4].

Epigenetics is a heritable change of gene expression or function by regulating the interaction between genome and environment without changing the basic sequence of DNA, mostly involving RNA modification, chromatin remodeling, histone modification, DNA methylation, etc. [5, 6]. RNA modification has become an active field of tumor research [7]. More than 60% of RNA modification is methylation modification. The most prevalent chemical alteration in eukaryotic mRNA is methylation at position m6A [8].

In cancer, the oxidative stress level increases [9]. Different proliferation signals, such as the combination of growth factor receptor and reduced nicotinamide adenine dinucleotide phosphate oxidase, cause the production of ROS to increase [10]. DNA mutation and uncontrolled cell proliferation...
caused by DNA oxidative damage are typical ROS tumorigen-

Oxidative stress refers to the stress state caused by the
imbalance of cell redox, excessive ROS accumulation, or
the decline of antioxidant capacity, resulting in the imbal-
ance between the body’s oxide and the antioxidant system
[13]. ROS is the normal product of an oxidation-reduction
reaction in the body [14]. It is produced by normal metabo-

lism or induced by exogenous factors such as smoking, radia-
tion, and dust, causing lipid peroxidation, causing DNA
strand breakage, oxidizing molecules in biofilm and tissue,
and causing damage [15]. However, because the body can
clear ROS to a certain extent, low-throughput ROS-
mediated redox signals can regulate cell cycle and cell prolif-
eration and play a central role. High-throughput ROS causes
irreversible changes in target molecules, which damages
cells, causes the continuous imbalance of redox homeostasis,
and eventually leads to cell death. This shows the necessity
of maintaining redox balance [16].

cGAS is a newly discovered DNA receptor. The cGAS/
STING signaling pathway has been implicated in the onset
and progression of numerous diseases in recent years,
according to an increasing number of studies [17]. A variety
of secretory phenotypes associated with ageing, such as oxidi-
dative stress, proinflammatory agents, chemokines, and pro-
teases, can also be released when the cGAS/STING route is
activated, which can accelerate the ageing of cancer cells
and slow tumor growth [18].

Recent studies have shown that PCBP2 can not only pro-
mote tumor growth in tumors but also low expression in
some tumors and may also play the role of tumor suppressor
genes [19–21]. The mechanism by which PCBP2 controls
the development and spread of glioma is yet unknown, and
study on the expression rate and clinical importance of
PCBP2 in glioblastoma has not been documented. In this
study, the impacts of PCBP2 on glioma patients and the
underlying mechanism were examined.

2. Materials and Methods

2.1. Patients. Patients with glioma were obtained from May
2017 to July 2018. Tissue samples were collected and imme-
diately stored at -80°C. None of the individuals did receive
radiotherapy or chemotherapy before surgery. All partici-
pants for this study from May 2017 to July 2018 have pro-
vided their written informed consent, and the Ethics
Committee of The Second Affiliated Hospital of Nanchang
University has approved this study.

2.2. Quantitative PCR and Microarray Analysis. Using a
LightCycler® 480 real-time PCR system, quantitative PCR
experiments were carried out (Roche, Germany). Reverse
transcription was performed on the total RNA from each
sample using an Invitrogen SuperScript double-stranded
cDNA synthesis kit. Following array hybridization using
the NimbleGen hybridization system, double-stranded
cDNA was performed using a NimbleGen one-color DNA
labelling kit, followed by washing with a NimbleGen wash
buffer kit. The microarray was scanned using a Molecular
Devices Axon GenePix 4000B scanner.
Figure 2: PCBP2 promoted the progression and metastasis of glioma. PCBP2 mRNA expression (a), cell growth (b), metastasis rate (c), and EdU (d) by PCBP2 upregulation; PCBP2 mRNA expression (e), cell growth (f), metastasis rate (g), and EdU (h) by PCBP2 downregulation. **p < 0.01 compared with vector or si-nc group.
Figure 3: Continued.
2.3. Cell Culture and RNA Interference. In RPMI 1640 media (Gibco, Carlsbad, CA, USA) enriched with 10% foetal calf serum (FCS, Gibco, Carlsbad, CA, USA), U251 cells (ATCC, HTX1725) were grown at 37 °C in a humidiﬁed environment with 5% CO2. U251 was transfected with plasmids using Lipofectamine 2000. The cells were employed in other studies 48 hours after transfection.

2.4. Western Blot Analysis. Using RIPA and PMSF reagent, total protein was recovered from cell samples (Beyotime, Beijing, China). On SDS/PAGE gels, protein lysates were divided according to their molecular weight before being transferred to a polyvinylidene ﬂuoride (PVDF, Millipore) membrane. After being blocked with nonfat milk (5%) at room temperature for 2 hours, the membranes were treated with an antibody at 4 °C overnight. The secondary antibody was applied to the membranes and left on them for two hours at ambient temperature.

2.5. Proliferation Assay, EdU Staining, and Oxidative Stress. CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, U.S.A.), in accordance with the manufacturer’s instructions, was used to measure cellular proliferation 48 hours after transfection for the Cell Counting Kit-8 (CCK-8) or ethynyl deoxyuridine (EdU) incorporation assay. The cells were ﬁxed with 4 percent formaldehyde for 30 minutes after EdU (10 mM) was introduced to each well. Following washing, the Click-iTR EdU Kit was used to detect EdU, and ﬂuorescence microscope images were used to view the results (Olympus). The following parameters were tested using kits and absorbance sing luminescent cell viability assay: CellTiter-Glo® (Promega, Madison, WI, U.S.A.)

2.6. Immunoﬂuorescence. After being permeabilized with 0.5 percent Triton X-100 in PBS for 15 minutes at room temperature and blocked with 5 percent BSA for 30 minutes at 37 °C, the cells were ﬁxed with 4 percent paraformaldehyde. After being exposed to primary antibodies at 4 °C overnight, the cells were incubated at 37 °C for 2 hours with secondary antibodies that were conjugated to Cy3 for goat anti-rabbit or goat anti-mouse IgG. The cells were examined using a ﬂuorescent illumination microscope after the nuclei were stained with DAPI (Olympus IX71, Tokyo, Japan).

2.7. Statistical Analysis. p < 0.05 was regarded as statistically signiﬁcant when data were analyzed using GraphPad 8.0 software and reported as the mean with standard deviation (mean ± SD). The Student’s t-test or two-way ANOVA with repeated measures, followed by the Tukey post hoc test, were used to assess the differences between the groups.

3. Results

3.1. PCBP2 Expression Level in Glioma Individuals. The expression of PCBP2 in glioma patients was ﬁrst veriﬁed. When compared to paracancerous tissue, PCBP2 mRNA and protein expressions were both upregulated in glioma...
patients (Figures 1(a) and 1(b)). OS and DFS of PCBP2 low expression in patients with glioma were higher than those of PCBP2 high expression (Figures 1(c) and 1(d)). Our data imply that PCBP2 had a critical role in the development of glioma when viewed together.

3.2. PCBP2 Promoted the Progression and Metastasis of Glioma. In the experiment, the role of PCBP2 in the development and metastasis of glioma was investigated. In U251 cells, the PCBP2 plasmid upregulated PCBP2 mRNA (Figure 2(a)). In U251 cells, overexpression of PCBP2 facilitated EdU cell migration, growth, and number (Figures 2(b)–2(d)). Si-PCBP2 reduced PCBP2 mRNA level in U251 cells (Figure 2(e)). Downregulation of PCBP2 reduced cell growth, migration rate, and number of EdU cells in U251 cells (HS683 cells, Figures 2(f)–2(h)). Therefore, we focused on Prok2 promoting the progression and metastasis of glioma.
Figure 5: PCBP2 protein interlinked with cGAS and cGAS was one target for PCBP2. PCBP2 protein interlinked with cGAS (IP, a); PCBP2 and cGAS (immunofluorescence, b); cGAS/STING protein expression by PCBP2 upregulation+cGAS agonist (c); cGAS/STING protein expression by PCBP2 upregulation+cGAS inhibitor (d). **p < 0.01 compared with vector or si-nc group.
3.3. PCBP2 Reduced Oxidative Stress-Induced Apoptosis of Glioma. We observed that PCBP2 control oxidative stress-induced apoptosis of glioma. Overexpression of PCBP2 reduced ROS and oxidative stress and inhibited apoptosis rate in U251 cells (Figures 3(a)–3(f)). Furthermore, the downregulation of PCBP2 promoted ROS and oxidative stress and heightened apoptosis rate in U251 cells (Figures 3(g)–3(l)). These results suggest that PCBP2 reduced oxidative stress-induced apoptosis of glioma.

3.4. PCBP2 Suppressed the cGAS/STING Pathway of Glioma. To directly examine the mechanism of PCBP2-regulated oxidative stress-induced apoptosis of glioma, we examined gene expression levels using microarray analysis (Figure 4(a)). We found that cGAS and STING may be two important targets of PCBP2 in glioma (Figures 4(a) and 4(b)). In U251 cells, the cGAS mRNA expression level was decreased by PCBP2 overexpression, whereas it was increased by PCBP2 downregulation (Figure 4(c)). In U251
cells, PCBP2 overexpression increased PCBP2 protein expression and decreased cGAS and STING protein expressions (Figures 4(e)–4(g)). In U251 cells, PCBP2 downregulation increased the expression of the cGAS and STING proteins while suppressing PCBP2 protein expression (Figures 4(h)–4(j)).

3.5. PCBP2 Protein Interlinked with cGAS and cGAS Was One Target for PCBP2. Based on these results, we explored the mechanism of PCBP2-regulated cGAS in glioma. We confirmed the association between PCBP2 and cGAS proteins by Co-IP (Figure 5(a)). Immunofluorescence showed that PCBP2 suppressed cGAS fluorescence expression in vitro (Figure 5(b)). cGAS agonist (SR-717, 1 μM) induced cGAS and STING protein expressions in U251 cells by PCBP2 upregulation (Figure 5(c)). cGAS inhibitor (2 μM of PF-06928215) suppressed cGAS and STING protein expressions in U251 cells by PCBP2 downregulation (Figure 5(d)). In general, data suggests that cGAS is one important target of PCBP2 in oxidative stress-induced apoptosis of glioma.

3.6. METTL3-Mediated m6A Modification Increases PCBP2 Stability. We further examined the mechanism of PCBP2 controlling the disease progression of glioma. Near the stop codon, we discovered that PCBP2 had numerous question-able methylation modification sites (Figure 6(a)). METTL3 knockout reduced PCBP2 mRNA levels and protein expression levels in U251 cells (Figures 6(b)–6(d)). The PCBP2 transcript was then subjected to sequence analysis, and two m6A sites were discovered in the 3′-untranslated region (UTR) (Figure 6(e)). At sites 1 and 2, m6A was considerably enriched (Figure 6(f)). m6A enrichment was decreased at sites 1 and 2 (Figure 6(g)). The transcription level of WT PCBP2 was reduced in the absence of METTL3, but the mutant PCBP2 did not (Figure 6(h)). According to these findings, PCBP2 stability is increased by m6A alteration caused by METTL3.

4. Discussion

One of the most prevalent cerebral malignant tumors, glioma, which develops from glial cells, has an annual recurrence rate of roughly 3.64/100000 [4]. Gliomas are divided into localized gliomas and diffuse gliomas. This paper mainly discusses diffuse gliomas. The primary malignant tumor of CNS with the highest frequency is glioma [22]. Even though surgery, adjuvant radiation, and chemotherapy are frequently employed today, the majority of patients still have dismal prognoses. Therefore, it is urgent to find a new treatment [23]. Our study discovered that PCBP2 mRNA expression level and protein expression in patients with glioma were upregulated compared with paracancerous tissue. PCBP2 promoted the progression and metastasis of glioma. Wang et al. demonstrated that PCBP2 induces breast cancer progression [24]. Therefore, PCBP2 contributed to the occurrence and growth of glioma as a repair factor.

On one hand, oxidative stress directly forms 8-oxoG or lipid peroxidation on DNA to cause distortion; on the other hand, it promotes the occurrence of glioma through epige-

netic mechanisms [25]. Site-specific epigenetic changes in glioma cells include methylation of E-cadherin promoter caused by H2O2 treatment and methylation of cytokine signal suppressor SOCS3 caused by HBV-induced mitochondrial ROS accumulation [26]. In general, the increase in ROS levels is the cause of genetic and epigenetic mutations and proliferation signals [27]. The imbalance of ROS caused by antioxidants will cause cell death [15, 16]. This study showed that PCBP2 reduced oxidative stress-induced apoptosis of glioma. Ishii et al. indicated that PCBP2 increased apoptosis under oxidative conditions [28]. Thus, it is possible that PCBP2 reduced oxidative stress-induced apoptosis of glioma.

A natural immunological signal system called cGAS-STING can detect aberrant DNA in cells [29, 30]. This signal system is crucial for the body’s immune response against harmful infections and tumors [31]. A number of autoimmune disorders can also be caused by the aberrant activation of this signal pathway [32]. According to studies, the cGAS-STING signaling pathway is mostly expressed in innate immune cells and is frequently expressed in the liver and other organs and cells [33, 34]. We revealed that PCBP2 suppressed the cGAS/STING pathway of glioma. PCBP2 protein interlinked with cGAS and cGAS was one target for PCBP2. Gu et al. demonstrated that PCBP2 inhibits cGAS condensation, which lowers cGAS enzyme activity [35]. Specifically, PCBP2 interacts with cGAS to reduce oxidative stress-induced apoptosis of glioma.

Studies already conducted have revealed that the cell cycle is significantly regulated by m6A RNA alteration, proliferation, metabolism, and biological origin of tumors by affecting RNA metabolism, which also opens up new ideas for glioma research and treatment [36, 37]. According to this study, PCBP2 stability is increased by m6A alteration caused by METTL3. To enhance the incidence and progression of glioma, METTL3-mediated m6A alteration specifically boosts PCBP2 stability.

As a result, our research shows for the first time that PCBP2 inhibited the cGAS-STING signal pathway, which causes oxidative stress to cause glioma cell death. In addition, blocking PCBP2 is a potential therapeutic approach for the management of gliomas. Our research also revealed a biochemical pathway that might be a possible target for preventing the glioma’s oxidative stress-induced death.

Data Availability

The data used to support this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Mingchuan Yu and Xiang Chen contributed equally to this work.
Acknowledgments

This study is supported by the National Key Research and Development Program of China (2020YFC2005800); Regional Funds of the National Natural Science Foundation of China (81760408 and 8156036); Project of the Science and Technology Department of Jiangxi Province, China (2018BCG42001); and Natural Science Foundation of Jiangxi Province, China (2011BCB22005).

References

[1] N. Elmadany, O. T. Alhalabi, M. Platten, and L. Bunse, “Site-specific considerations on engineered T cells for malignant gliomas,” Biomedicine, vol. 10, no. 7, p. 1738, 2022.

[2] M. Guaraccia, L. Guaraccia, V. La Cognata et al., “A targeted next-generation sequencing panel to genotype gliomas,” Life, vol. 12, no. 7, p. 956, 2022.

[3] K. Huang, H. Wang, J. Xu et al., “The tropomyosin family as novel biomarkers in relation to poor prognosis in glioma,” Biology, vol. 11, no. 8, p. 1115, 2022.

[4] L. H. T. Lam, N. T. Chu, T. D. To, and N. Q. K. Le, “A radiomics-based machine learning model for prediction of tumor mutational burden in lower-grade gliomas,” Cancers, vol. 14, no. 14, p. 3492, 2022.

[5] P. Cong, T. Wu, X. Huang et al., “Identification of the role and clinical prognostic value of target genes of m6A RNA methyl- ation regulators in glioma,” Frontiers in Cell and Development Biology, vol. 9, p. 709022, 2021.

[6] D. Dixit, B. C. Prager, R. C. Gimple et al., “The RNA m6A reader YTHDF2 maintains oncogene expression and is a tar- getable dependency in glioblastoma stem cells,” Cancer Discovery, vol. 11, no. 2, pp. 480–499, 2021.

[7] J. Du, H. Ji, S. Ma et al., “m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma,” Briefings in Bioinformatics, vol. 22, no. 5, 2021.

[8] Y. Z. Chang, R. C. Chai, B. Pang et al., “METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modi- fication and activates NF-κB to promote the malignant prog- ression of IDH-wildtype glioma,” Cancer Letters, vol. 511, pp. 36–46, 2021.

[9] J. Y. Chang, Y. Hu, E. Siegel, L. Stanley, and Y. H. Zhou, “PAX6 increases glioma cell susceptibility to detachment and oxidative stress,” Journal of Neuro-Oncology, vol. 84, no. 1, pp. 9–19, 2007.

[10] X. Cheng, F. Geng, M. Pan et al., “Targeting DGAT1 amelio- rates glioblastoma by increasing fat catabolism and oxidative stress,” Cell Metabolism, vol. 32, no. 2, pp. 229–242.e8, 2020, e228.

[11] G. Bridge, S. Rashid, and S. A. Martin, “DNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment,” Cancers, vol. 6, no. 3, pp. 1597–1614, 2014.

[12] Z. Pu, M. Xu, X. Yuan, H. Xie, and J. Zhao, “Circular RNA cir-cCUL3 accelerates the Warburg effect progression of gastric cancer through regulating the STAT3/HK2 Axis,” Mol Ther Nucleic Acids, vol. 22, pp. 310–318, 2020.

[13] S. Tomkova, M. Misuth, L. Lenkovska, P. Miskovsky, and V. Huntosova, “In vitro identification of mitochondrial oxidative stress production by time-resolved fluorescence imaging of glioma cells,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1865, no. 4, pp. 616–628, 2018.

[14] L. Wu, F. Wang, J. Xu, and Z. Chen, “PTPN2 induced by inflammatory response and oxidative stress contributed to gli- oma progression,” Journal of Cellular Biochemistry, vol. 120, no. 11, pp. 19044–19051, 2019.

[15] R. P. Ostrowski and E. B. Pucko, “Harnessing oxidative stress for anti-glioma therapy,” Neurochemistry International, vol. 154, p. 105281, 2022.

[16] H. Zhou, L. Han, H. Wang, J. Wei, Z. Guo, and Z. Li, “Chida- mide inhibits glioma cells by increasing oxidative stress via the miRNA-338-5p regulation of hedgehog signaling,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 7126976, 17 pages, 2020.

[17] B. Chen, X. Rao, X. Wang et al., “cGAS-STING signaling path- way and liver disease: from basic research to clinical practice,” Frontiers in Pharmacology, vol. 12, p. 719644, 2021.

[18] R. Chen, J. Du, H. Zhu, and Q. Ling, “The role of cGAS-STING signalling in liver diseases,” JHEP Rep, vol. 3, no. 5, p. 100324, 2021.

[19] Y. Li, Z. Zhao, C. Y. Lin et al., “Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer,” Theranostics, vol. 11, no. 5, pp. 2182–2200, 2021.

[20] J. Mao, Z. Sun, Y. Cui et al., “PCBP2 promotes the develop- ment of glioma by regulating FHL3/TGF-β-Smad signaling pathway,” Journal of Cellular Physiology, vol. 235, no. 4, pp. 3280–3291, 2020.

[21] T. Yabe-Wada, C. C. Philpott, and N. Onai, “PCBP2 post- transcriptionally regulates sorbitol expression by binding to a C-rich element in its 3’ UTR,” FEBS Open Bio, vol. 10, no. 3, pp. 407–413, 2020.

[22] B. Muocio, D. Albano, F. Dondi et al., “Diagnostic accuracy of PET/CT or PET/MRI using PSMA-targeting radiopharmaceuti- cals in high-grade gliomas: a systematic review and a bivariate meta-analysis,” Diagnostics, vol. 12, no. 7, p. 1665, 2022.

[23] J. Ortiz-Rivera, A. Albors, Y. Kucheryavykh, J. K. Harrison, and L. Kucheryavykh, “The dynamics of tumor-infiltrating myeloid cell activation and the cytokine expression profile in a glioma resection site during the post-surgical period in mice,” Brain Sciences, vol. 12, no. 7, p. 893, 2022.

[24] X. Wang, Q. Guo, H. Wang et al., “PCBP2 posttranscriptional modifications induce breast cancer progression via upregula- tion of UFD1 and NT5E,” Molecular Cancer Research, vol. 19, no. 1, pp. 86–98, 2021.

[25] S. H. Kim, C. H. Kwon, and I. Nakano, “Detoxification of oxi- dative stress in glioma stem cells: mechanism, clinical relevance, and therapeutic development,” Journal of Neuroscience Research, vol. 92, no. 11, pp. 1419–1424, 2014.

[26] L. Zheng, C. Wang, T. Luo et al., “JNK activation contributes to oxidative stress-induced p38mitos in glioma cells via increase of intracellular ROS production,” Molecular Neurobiol- ogy, vol. 54, no. 5, pp. 3492–3505, 2017.

[27] W. Zhang, W. Wang, M. Xu, H. Xie, and Z. Pu, “GPR43 regu- lation of mitochondrial damage to alleviate inflammatory reaction in sepsis,” Aging, vol. 13, no. 18, pp. 22588–22610, 2021.

[28] T. Ishii, T. Igawa, H. Hayakawa, T. Fujita, M. Sekiguchi, and Y. Nakabeppu, "PCBP1 and PCBP2 both bind heavily oxidized RNA but cause opposing outcomes, suppressing or increasing apoptosis under oxidative conditions," The Journal of Biological Chemistry, vol. 295, no. 34, pp. 12247–12261, 2020.
[29] S. Xu, X. Yan, L. Tang, G. Dai, and C. Luo, “A nanoparticle-conjugated anti-TBK1 siRNA induces autophagy-related apoptosis and enhances cGAS-STING pathway in GBM cells,” *Evidence-based Complementary and Alternative Medicine*, vol. 2021, Article ID 6521953, 13 pages, 2021.

[30] M. Jiang, P. Chen, L. Wang et al., “cGAS-STING, an important pathway in cancer immunotherapy,” *Journal of Hematology & Oncology*, vol. 13, no. 1, p. 81, 2020.

[31] B. Weenink, K. Draaisma, H. Z. Ooi et al., “Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens,” *Scientific Reports*, vol. 9, no. 1, p. 14643, 2019.

[32] Y. Wang, J. Luo, A. Alu, X. Han, Y. Wei, and X. Wei, “cGAS-STING pathway in cancer biotherapy,” *Molecular Cancer*, vol. 19, no. 1, p. 136, 2020.

[33] P. S. Yao, D. Z. Kang, R. Y. Lin, B. Ye, W. Wang, and Z. C. Ye, “Glutamate/glutamine metabolism coupling between astrocytes and glioma cells: neuroprotection and inhibition of glioma growth,” *Biochemical and Biophysical Research Communications*, vol. 450, no. 1, pp. 295–299, 2014.

[34] H. Du, T. Xu, and M. Cui, “cGAS-STING signaling in cancer immunity and immunotherapy,” *Biomedicine & Pharmacotherapy*, vol. 133, p. 110972, 2021.

[35] H. Gu, J. Yang, J. Zhang et al., “PCBP2 maintains antiviral signaling homeostasis by regulating cGAS enzymatic activity via antagonizing its condensation,” *Nature Communications*, vol. 13, no. 1, p. 1564, 2022.

[36] N. Tao, T. Wen, T. Li, L. Luan, H. Pan, and Y. Wang, “Interaction between m6A methylation and noncoding RNA in glioma,” *Cell Death Discov*, vol. 8, no. 1, p. 283, 2022.

[37] Y. Zhang, X. Geng, Q. Li et al., “m6A modification in RNA: biogenesis, functions and roles in gliomas,” *Journal of Experimental & Clinical Cancer Research*, vol. 39, no. 1, p. 192, 2020.